Solid Biosciences
SLDB
39 hedge funds and large institutions have $74.8M invested in Solid Biosciences in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 6 closing their positions.
138% more capital inflows, than outflows
Capital inflows: $5.8M | Capital outflows: $2.43M
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
80.6% more ownership
Funds ownership: 0% → 80.6% (+81%)
15% more funds holding
Funds holding: 34 → 39 (+5)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Finepoint Capital
Boston,
Massachusetts
|
+$1.62M |
| 2 |
Pura Vida Investments
New York
|
+$1.35M |
| 3 |
Great Point Partners
Greenwich,
Connecticut
|
+$1.26M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$640K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$1.84M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$235K |
| 3 |
Renaissance Technologies
New York
|
-$78.1K |
| 4 |
Millennium Management
New York
|
-$69K |
| 5 |
Old Well Partners
Charlotte,
North Carolina
|
-$58.1K |
SLDB Hedge Fund Activity: Q1 2023 in Review
39 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q1 2023, worth a combined $74.8M — down 12% from $85.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SLDB positions and 6 closed out — a net gain of 5 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was Finepoint Capital, adding an estimated $1.62M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $1.84M sold.
- 39 institutional investors held Solid Biosciences (SLDB) as of Q1 2023, up from 34 in Q4 2022.
- Funds reported $74.8M of Solid Biosciences stock for Q1 2023, down 12% quarter-over-quarter.
- 11 funds opened new Solid Biosciences positions in Q1 2023 and 6 closed out, a net change of +5 holders.
- The largest Solid Biosciences buyer in Q1 2023 was Finepoint Capital, an estimated $1.62M added.
- The largest Solid Biosciences seller in Q1 2023 was K2 Principal Fund, an estimated $1.84M sold.
Based on aggregated 13F filings for Q1 2023.